FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3157488875> ?p ?o ?g. }

• W3157488875 endingPage "1689" @default.
• W3157488875 startingPage "1680" @default.
• W3157488875 abstract "Prolyl-tRNA synthetase (PRS) is a clinically validated antimalarial target. Screening of a set of PRS ATP-site binders, initially designed for human indications, led to identification of 1-(pyridin-4-yl)pyrrolidin-2-one derivatives representing a novel antimalarial scaffold. Evidence designates cytoplasmic PRS as the drug target. The frontrunner 1 and its active enantiomer 1-S exhibited low-double-digit nanomolar activity against resistant Plasmodium falciparum (Pf) laboratory strains and development of liver schizonts. No cross-resistance with strains resistant to other known antimalarials was noted. In addition, a similar level of growth inhibition was observed against clinical field isolates of Pf and P. vivax. The slow killing profile and the relative high propensity to develop resistance in vitro (minimum inoculum resistance of 8 × 105 parasites at a selection pressure of 3 × IC50) constitute unfavorable features for treatment of malaria. However, potent blood stage and antischizontal activity are compelling for causal prophylaxis which does not require fast onset of action. Achieving sufficient on-target selectivity appears to be particularly challenging and should be the primary focus during the next steps of optimization of this chemical series. Encouraging preliminary off-target profile and oral efficacy in a humanized murine model of Pf malaria allowed us to conclude that 1-(pyridin-4-yl)pyrrolidin-2-one derivatives represent a promising starting point for the identification of novel antimalarial prophylactic agents that selectively target Plasmodium PRS." @default.
• W3157488875 created "2021-05-10" @default.
• W3157488875 creator A5001000902 @default.
• W3157488875 creator A5003948569 @default.
• W3157488875 creator A5004689772 @default.
• W3157488875 creator A5015175584 @default.
• W3157488875 creator A5017098545 @default.
• W3157488875 creator A5018262996 @default.
• W3157488875 creator A5031843900 @default.
• W3157488875 creator A5033001331 @default.
• W3157488875 creator A5037632984 @default.
• W3157488875 creator A5038988231 @default.
• W3157488875 creator A5041462900 @default.
• W3157488875 creator A5042693001 @default.
• W3157488875 creator A5042851900 @default.
• W3157488875 creator A5044913327 @default.
• W3157488875 creator A5044969186 @default.
• W3157488875 creator A5050385668 @default.
• W3157488875 creator A5052321084 @default.
• W3157488875 creator A5052852656 @default.
• W3157488875 creator A5054827010 @default.
• W3157488875 creator A5056150539 @default.
• W3157488875 creator A5059081442 @default.
• W3157488875 creator A5063561497 @default.
• W3157488875 creator A5067544706 @default.
• W3157488875 creator A5067566321 @default.
• W3157488875 creator A5071314941 @default.
• W3157488875 creator A5072487061 @default.
• W3157488875 creator A5079070373 @default.
• W3157488875 creator A5091489538 @default.
• W3157488875 date "2021-04-30" @default.
• W3157488875 modified "2023-10-02" @default.
• W3157488875 title "Repositioning and Characterization of 1-(Pyridin-4-yl)pyrrolidin-2-one Derivatives as <i>Plasmodium</i> Cytoplasmic Prolyl-tRNA Synthetase Inhibitors" @default.
• W3157488875 cites W1771852563 @default.
• W3157488875 cites W1773613920 @default.
• W3157488875 cites W1972907204 @default.
• W3157488875 cites W2003127960 @default.
• W3157488875 cites W2006158992 @default.
• W3157488875 cites W2016772121 @default.
• W3157488875 cites W2044242984 @default.
• W3157488875 cites W2137198187 @default.
• W3157488875 cites W2138741610 @default.
• W3157488875 cites W2154168118 @default.
• W3157488875 cites W2155796970 @default.
• W3157488875 cites W2164397421 @default.
• W3157488875 cites W2171875683 @default.
• W3157488875 cites W2239955096 @default.
• W3157488875 cites W2320132985 @default.
• W3157488875 cites W2340274773 @default.
• W3157488875 cites W2395785188 @default.
• W3157488875 cites W2512605033 @default.
• W3157488875 cites W2542763137 @default.
• W3157488875 cites W2573624079 @default.
• W3157488875 cites W2578571452 @default.
• W3157488875 cites W2612257830 @default.
• W3157488875 cites W2766048691 @default.
• W3157488875 cites W2767108732 @default.
• W3157488875 cites W2782288120 @default.
• W3157488875 cites W2912372464 @default.
• W3157488875 cites W2938448257 @default.
• W3157488875 cites W2952725991 @default.
• W3157488875 cites W2970680432 @default.
• W3157488875 cites W2972001820 @default.
• W3157488875 cites W3030437205 @default.
• W3157488875 cites W38259148 @default.
• W3157488875 cites W4243658490 @default.
• W3157488875 doi "https://doi.org/10.1021/acsinfecdis.1c00020" @default.
• W3157488875 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8204304" @default.
• W3157488875 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33929818" @default.
• W3157488875 hasPublicationYear "2021" @default.
• W3157488875 type Work @default.
• W3157488875 sameAs 3157488875 @default.
• W3157488875 citedByCount "11" @default.
• W3157488875 countsByYear W31574888752021 @default.
• W3157488875 countsByYear W31574888752022 @default.
• W3157488875 countsByYear W31574888752023 @default.
• W3157488875 crossrefType "journal-article" @default.
• W3157488875 hasAuthorship W3157488875A5001000902 @default.
• W3157488875 hasAuthorship W3157488875A5003948569 @default.
• W3157488875 hasAuthorship W3157488875A5004689772 @default.
• W3157488875 hasAuthorship W3157488875A5015175584 @default.
• W3157488875 hasAuthorship W3157488875A5017098545 @default.
• W3157488875 hasAuthorship W3157488875A5018262996 @default.
• W3157488875 hasAuthorship W3157488875A5031843900 @default.
• W3157488875 hasAuthorship W3157488875A5033001331 @default.
• W3157488875 hasAuthorship W3157488875A5037632984 @default.
• W3157488875 hasAuthorship W3157488875A5038988231 @default.
• W3157488875 hasAuthorship W3157488875A5041462900 @default.
• W3157488875 hasAuthorship W3157488875A5042693001 @default.
• W3157488875 hasAuthorship W3157488875A5042851900 @default.
• W3157488875 hasAuthorship W3157488875A5044913327 @default.
• W3157488875 hasAuthorship W3157488875A5044969186 @default.
• W3157488875 hasAuthorship W3157488875A5050385668 @default.
• W3157488875 hasAuthorship W3157488875A5052321084 @default.
• W3157488875 hasAuthorship W3157488875A5052852656 @default.
• W3157488875 hasAuthorship W3157488875A5054827010 @default.
• W3157488875 hasAuthorship W3157488875A5056150539 @default.
• W3157488875 hasAuthorship W3157488875A5059081442 @default.

• next